市場調查報告書
商品編碼
1547592
全球凝血酶原複合濃縮物市場研究報告 - 2024 年至 2032 年產業分析、規模、佔有率、成長、趨勢與預測Global Prothrombin Complex Concentrate Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032 |
預計到 2032 年,全球凝血酶原複合濃縮物市場的市場規模將從 2023 年的 8,5551 萬美元達到近 9,1094 萬美元,2024-2032 年研究期間複合年成長率為 0.7%。
凝血酶原複合物濃縮物是一種用作藥物的止血血液製品。它由凝血因子 II、IX、X,有時還有凝血因子 VII 組成。該濃縮物能夠逆轉華法林和其他維生素 K 抗凝血劑的作用。它用於患有凝血功能障礙的人的嚴重出血病例或此類患者接受緊急手術治療時。它也用於因先天性、肝病或血友病而缺乏一種凝血因子的人。它是透過直接緩慢注射到人類靜脈中進行給藥的。它是透過對大量血漿池的冷沉澱上清液進行離子交換色譜法並去除抗凝血酶和因子 XI 來產生的。
出血性疾病盛行率的增加和政府對創新醫療療法的批准放寬是有利於市場成長的促進因素。由於 PCC 的高臨床效率,用於治療外科手術期間不必要的過度出血的需求不斷成長,這將有利於市場的成長。華法林療法的日益使用以及凝血酶原複合物在快速逆轉華法林相關顱內出血患者凝血障礙方面的高效作用將促進市場成長。增加對治療凝血障礙新藥研發的投資以及改善醫療基礎設施將是市場的助推器。缺乏認知和這些藥物的副作用可能會對市場成長產生沉重影響。
研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外,這些工具還對凝血酶原複合濃縮物全球市場的每個細分市場進行了包容性評估。凝血酶原複合濃縮物產業的成長和趨勢為本研究提供了整體方法。
凝血酶原複合濃縮物市場報告的這一部分提供了國家和區域層面的細分市場的詳細資料,從而幫助策略師確定相應產品或服務的目標人口統計數據以及即將到來的機會。
本節涵蓋區域前景,重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲的凝血酶原複合濃縮物市場當前和未來的需求。此外,該報告重點關注所有主要地區各個應用領域的需求、估計和預測。
該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。凝血酶原複合濃縮物市場的主要參與者包括 CSL、Octapharma AG、Kedrion、武田藥品工業株式會社、泰邦生物Group Limited、Sanquin、Grifols、SA、Biotest AG、Abeona Therapeutics Inc.、Insud Pharma。本節包含競爭格局的整體視圖,包括各種策略發展,例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。
如果您有任何客製化要求,請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。
The global demand for Prothrombin Complex Concentrate Market is presumed to reach the market size of nearly USD 910.94 Million by 2032 from USD 855.51 Million in 2023 with a CAGR of 0.7% under the study period 2024-2032.
Prothrombin complex concentrate is a hemostatic blood product used as medication. It is made up of blood clotting factors II, IX, X, and sometimes factor VII. This concentrate has the ability to reverse the effects of warfarin and other vitamin K anticoagulants. It is used in significant bleeding cases in people with coagulopathy or when such patients undergo an emergency operation treatment. It is also used in people with a deficiency of one of the clotting factors because of congenital, liver disease, or hemophilia. It is administered using a slow injection directly into the human vein. It is produced by the ion-exchange chromatography of the cryoprecipitate supernatant of large plasma pools and antithrombin and factor XI removal.
The increased prevalence of bleeding disorders and eased government approval for innovative medical therapies are few driving factors favoring the market growth. The rising demand for PCC for treating unwanted excessive bleeding during surgical procedures due to its high clinical efficiency will benefit the market's growth. The growing use of warfarin therapy and the high efficiency of prothrombin complex concentrates in rapidly reversing coagulopathy in patients with warfarin-related intracranial hemorrhage will enhance the market growth. Increased investments in the research and development of new drugs to treat blood clotting disorders and improving healthcare infrastructure will be a market booster. Lack of awareness and the side effects of these medications can have a burdening impact on market growth.
The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Prothrombin Complex Concentrate. The growth and trends of Prothrombin Complex Concentrate industry provide a holistic approach to this study.
This section of the Prothrombin Complex Concentrate market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
This section covers the regional outlook, which accentuates current and future demand for the Prothrombin Complex Concentrate market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Prothrombin Complex Concentrate market include CSL, Octapharma AG, Kedrion, Takeda Pharmaceutical Company Limited., Taibang Biological Group Co. Ltd., Sanquin, Grifols, S.A., Biotest AG, Abeona Therapeutics Inc., Insud Pharma. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.